OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit
04 déc. 2023 07h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of...
Omnix Medical Receives U.S. FDA Approval of a Phase II Trial of its Next-Generation Anti-Infective OMN6
20 nov. 2023 04h00 HE
|
AKAMPION
- Phase I data show safety and tolerability at clinically significant dose levels- New class of anti-infectives to treat infections with Gram-negative bacteria JERUSALEM, Israel, November 20,...
Medical Devices Testing Services Market Size Worth USD 22.43 Billion in 2032 | Emergen Research
15 nov. 2023 12h24 HE
|
Emergen Research
Vancouver, Nov. 15, 2023 (GLOBE NEWSWIRE) -- The global Medical Devices Testing Services Market will be worth USD 22.43 Billion by 2032, according to a current analysis by Emergen Research. The...
Blueberry Therapeutics Meets Primary and Secondary Endpoints in Phase 2b Trial in Onychomycosis
13 nov. 2023 02h00 HE
|
Blueberry Therapeutics
Blueberry Therapeutics Meets Primary and Secondary Endpoints in Phase 2b Trial in Onychomycosis Primary endpoint (negative culture and/or clear nail growth) met with 83.3% response rate Secondary...
TLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Session at ACR
08 nov. 2023 04h54 HE
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 08, 2023 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a late clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment
18 oct. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
Patients In the Intermediate Size Patient Population Expanded Access (EA) Program Will Receive Intranasal Foralumab As Part of the At-Home Dosing InitiativeGreater Than 1 year Safety Exposure to...
Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab
16 oct. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
Numeric improvements were seen across key multiple sclerosis measures, including the Modified Fatigue Impact Scale, Expanded Disability Status Scale, Timed 25-Foot Walk test, Pyramidal Scores and...
Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)
13 oct. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
Five out of six patients in FDA authorized Expanded Access Program are showing a qualitative reduction in microglia activation (a key biomarker being observed)Foralumab to advance into Phase 2 human...
[Latest] Global Mental Health Technology Market Size/Share Worth USD 18.9 Billion by 2032 at a 16% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
25 sept. 2023 18h30 HE
|
Custom Market Insights
Austin, TX, USA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Mental Health Technology Market Size, Trends and Insights By Functionality...
OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease
08 sept. 2023 07h00 HE
|
OKYO Pharma LTD
Full enrollment achieved on September 6th with a total of 240 patients enrolled in studyTop-line data planned for release in December 2023Phase 2 trial is designed as a potential registration trial,...